Looking to join a young and innovative #biotech company and support the development of novel meaningful growth factor-targeting therapeutics? We currently have two #Job openings, so head over to our careers page and apply now: agomab.com/careers/ #Hiring

Do you want to work at the forefront of biotech innovation? We are growing our dynamic team and are currently #hiring for a variety of open positions at different levels. Join us to be a part of our transformative journey in regenerative medicine: agomab.com/careers/

We are thrilled to be one of FierceBiotech's #Fierce15 companies 22, honoring breakthrough innovations in the biotech sphere. Our approach focuses on targeting growth factors to transform the therapeutic landscape of fibrotic related diseases. Learn more: agomab.com

Up for a challenge in a young, up and coming #biotech company? We continue to grow our team and currently have several #jobopenings in different departments. To learn more & apply click: lnkd.in/dcq4_w8

Congratulations to our CEO Tim Knotnerus for winning “Private Company CEO of the Year” at yesterday’s LSX Leaders #EuropeanLifestarsAwards in London. Onwards and upwards #TeamAgomab!

At the beginning of 2023, we want to thank our team members, partners & investors for their continuous support over the past year. We look forward to rapidly advance our pipeline of growth factor-modulating therapeutics & further expand our growing team in 2023. #HappyNewYear

Don’t miss out when our CEO Tim Knoterus is presenting Agomab on January 11, 3pm PT, at the 41st Annual J.P. Morgan #Healthcare Conference in San Francisco. See all upcoming conferences here: bit.ly/3i6AfA8

An important step in developing treatment options for #CrohnsDisease: today we announced the positive results from our Phase 1 study with AGMB-129, a GI-restricted ALK5 inhibitor intended for the treatment of fibrostenosing Crohn’s disease: agomab.com/wp-content/upl…

As we grow the #Agomab team, we’d like to introduce you to the latest 5 additions, joining us on our mission to treat #fibrosis. Welcome aboard! 🚀 Learn more about how we target #GrowthFactor pathways for fibrotic indications here agomab.com

At Agomab we #EmbraceEquity & value diversity in our team and work culture. On #InternationalWomensDay we raise awareness for the disparities still existing & celebrate all the women Agomab that are integral to our mission of developing better treatments for fibrotic diseases.

Join our leadership team at upcoming industry conferences this spring where we discuss our approach to developing new therapeutics with disease-modifying potential aimed at bringing innovation to the treatment of fibrotic diseases! See all conferences here bit.ly/3i6AfA8

Last Thursday, we celebrated our growing team in Antwerp, Belgium, with all Agomab staff from Belgium, the Netherlands, France, the UK, Spain and Italy! Are you interested in joining our enthusiastic and dynamic team? Access our latest job openings at: agomab.com/careers/

Today we announced that AGMB-129 received FDA Fast Track Designation for fibrostenosing Crohn’s Disease and that our Phase 2a STENOVA trial is underway. Two crucial steps in addressing this unmet medical need: agomab.com/news-events/#n… #FDAFastTrack #CrohnsDisease #Biotech

We are excited to close our $100M Series C funding round led by Fidelity Investments, with support from new investors EQT, Canaan, and Dawn Biopharma, along with existing backers. Funds will help us advance our fibrotic disease drug candidates. Learn more: agomab.com/news-events/

Very proud about the appointments of two female leaders to the board and executive team. Angelika Jahreis, MD, PhD, and SVP at Novartis, will join the Board of Directors while Andrea Sáez, PhD will be promoted to Chief Development Officer.

We’ve dosed the first subject in our Phase 1 clinical study with AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5. Designed to combat fibrosis in the respiratory tract, AGMB-447 has the potential to become a new treatment for #IPF patients.

Join us in Washington, DC on May 20, 6 pm at Marriott Marquis for our symposium on fibrostenosing Crohn’s disease. The meeting will feature a live patient testimonial, along with commentary from leading IBD experts, Dr. Florian Rieder, Dr. Cathy Lu, and Dr. Brian Feagan.

Our small molecule ALK5 inhibitor, AGMB-447, has been granted Orphan Drug Designation by the FDA, providing further support for its potential in addressing IPF. Read more here agomab.com #IPF #OrphanDrug

Join us in welcoming David Epstein as Chairman of the Board at Agomab. With 30+ years in the biopharma industry, David’s experience will help us advance our candidates for fibrotic diseases. Read more here 20240709_Agomab-David-Epstein-Appointment_FINAL.pdf #Agomab

We welcome Pierre Kemula as Agomab’s new CFO, effective November 1st. With 15+ years in global biotech finance, Pierre’s expertise will be vital for Agomab’s next phase of growth. Read more here 20240711-Agomab-PR-Pierre-Kemula-CFO.pdf